Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation of Chemotherapy in Early-Stage HER2+ Breast Cancer
NCT04419181Phase 2Withdrawn
- Sponsor
- University of Rochester
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine, pertuzumab in HER2-positive breast cancer, sponsored by University of Rochester. Planned start Aug 2025; status: withdrawn.
02
Drugs
trastuzumab emtansinepertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04419181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419181.